Newsletter
Continuous Glucose Monitoring in T1DM, Ticragelor vs DAPT in ACS, Nasal ACE2 Levels and COVID-19 in Children, and more

JAMA Editor’s Summary

Continuous Glucose Monitoring in T1DM, Ticragelor vs DAPT in ACS, Nasal ACE2 Levels and COVID-19 in Children, and more

Editor's Summary by Howard Bauchner, MD, Editor in Chief of JAMA, the Journal of the American Medical Association, for the
June 16, 2020

Continuous Glucose Monitoring in T1DM, Ticragelor vs DAPT in ACS, Nasal ACE2 Levels and COVID-19 in Children, and more

Editor’s Summary by Howard Bauchner, MD, Editor in Chief of JAMA, the Journal of the American Medical Association, for the June 16, 2020 issue

You may also like

The Latest Health Podcasts. Delivered to Your Inbox.

Join Our Newsletter

Proudly supported by:

cover
A Diverse Skill Set Peter McCanna is chief executive officer (CEO) at Baylor Scott & White Health, the largest not- for-profit health system in Texas. Through 51 hospitals and more than 1,200 access points, including flagship academic medical centers in Dallas, Fort Worth and Temple, the system offers the full continuum of care, from primary to award-winning specialty care, as well as an array of virtual and in-home services.